Abstract P477: A Meta-Analysis of Carotid Stenting and Angioplasty for Treatment of Tandem Occlusion Stroke

Introduction: Acute ischemic stroke (AIS) in the setting of tandem extracranial carotid disease and intracranial large vessel occlusion (TO) is associated with poor functional outcome. It remains unclear whether the extracranial lesion requires acute stenting or angioplasty alone. Meta-analyses to date have included predominantly retrospective non-comparative series. Our meta-analysis aimed to investigate if emergent carotid stenting plus endovascular thrombectomy (EVT) is more effective than angioplasty alone plus EVT at reducing incomplete recanalization (TICI <2b/3), symptomatic ICH (sICH) rate, or poor functional outcome (mRS>2 90 days). Methods: Systematic review identifying TO studies comparing those undergoing carotid angioplasties alone to stenting. Results were pooled using inverse variance random effects meta-analyses. Conclusions accounted for the magnitude of effect, precision and risk of bias in the studies using the modified GRADE process of the American Academy of Neurology. Results: Ten non-blinded, observational studies totaling 1006 TO patients met inclusion criteria. Baseline patient characteristics were without significant confounders. Mean initial NIHSS was 15.3 and 15.0 and symptom onset-to-recanalization time was 332 and 337 minutes in the stenting and angioplasty groups, respectively. Overall, poor functional outcome at 90 days occurred in 44.6% of patients and death occurred in 13.0% of patients. There was a significant decrease in the rate of mRS>2 (OR=0.55, CI 95% 0.40 –0.76) and death (OR=0.47, CI 95% 0.24–0.94) in patients treated with stenting vs angioplasty. TICI <2b/3 occurred in 21.5% of patients overall with no statistical difference in patients treated with stenting vs angioplasty (OR=0.67, CI 95% 0.42—1.07). sICH occurred in 5.7% of patients overall and there was no statistical difference in patients treated with stenting vs angioplasty (OR=1.19, CI 95% 0.53—2.67). Conclusion: Emergent stenting possibly decreases the risk of mRS>2 and mortality at 90 days. There is insufficient evidence to conclude whether stenting increases the risk of TICI <2b/3 and sICH. Confidence in the evidence is low, anchored by observational study designs and absence of blinding. A randomized controlled study is warranted.

Download Full-text

Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp-2018-318483 ◽

2018 ◽

Vol 90 (1) ◽

pp. 75-83 ◽

Cited By ~ 21

Author(s):

Oliver Jonathan Ziff ◽

Gargi Banerjee ◽

Gareth Ambler ◽

David J Werring

Keyword(s):

Statin Therapy ◽

Functional Outcome ◽

Intracerebral Haemorrhage ◽

Meta Analysis ◽

Stroke Subtype ◽

Poor Functional Outcome ◽

Registration Number ◽

Meta Analyses ◽

And Function

ObjectiveWhether statins increase the risk of intracerebral haemorrhage (ICH) in patients with a previous stroke remains uncertain. This study addresses the evidence of statin therapy on ICH and other clinical outcomes in patients with previous ischaemic stroke (IS) or ICH.MethodsA systematic literature review and meta-analysis was performed in conformity with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to assess observational and randomised studies comparing statin therapy with control (placebo or no treatment) in patients with a previous ICH or IS. The risk ratios (RR) for the primary outcome (ICH) and secondary outcomes (IS, any stroke, mortality and function) were pooled using random effects meta-analysis according to stroke subtype.ResultsForty-three studies with a combined total of 317 291 patient-years of follow-up were included. In patients with previous ICH, statins had no significant impact on the pooled RR for recurrent ICH (1.04, 95% CI 0.86 to 1.25; n=23 695); however, statins were associated with significant reductions in mortality (RR 0.49, 95% CI 0.36 to 0.67; n=89 976) and poor functional outcome (RR 0.71, 95% CI 0.67 to 0.75; n=9113). In patients with previous IS, statins were associated with a non-significant increase in ICH (RR 1.36, 95% CI 0.96 to 1.91; n=103 525), but significantly lower risks of recurrent IS (RR 0.74, 95% CI 0.66 to 0.83; n=53 162), any stroke (RR 0.82, 95% CI 0.67 to 0.99; n=55 260), mortality (RR 0.68, 95% CI 0.50 to 0.92; n=74 648) and poor functional outcome (RR 0.83, 95% CI 0.76 to 0.91; n=34 700).ConclusionsIrrespective of stroke subtype, there were non-significant trends towards future ICH with statins. However, this risk was overshadowed by substantial and significant improvements in mortality and functional outcome among statin users.Trial registration numberCRD42017079863.

Download Full-text

Contrast extravasation and outcome of endovascular therapy in acute ischaemic stroke: a systematic review and meta-analysis

BMJ Open ◽

10.1136/bmjopen-2020-044917 ◽

2021 ◽

Vol 11 (7) ◽

pp. e044917

Author(s):

Tao Xu ◽

You Wang ◽

Jinxian Yuan ◽

Yangmei Chen ◽

Haiyan Luo

Keyword(s):

Systematic Review ◽

Ischaemic Stroke ◽

Functional Outcome ◽

Endovascular Therapy ◽

Acute Ischaemic Stroke ◽

Data Extraction ◽

Meta Analysis ◽

Poor Functional Outcome ◽

Eligibility Criteria ◽

Contrast Extravasation

ObjectiveContrast extravasation (CE) after endovascular therapy (EVT) is commonly present in acute ischaemic stroke (AIS) patients. Substantial uncertainties remain about the relationship between CE and the outcomes of EVT in patients with AIS. Therefore, we aimed to evaluate this association.DesignA systematic review and meta-analysis of published studies were performed.Data sourceWe systematically searched the Medline and Embase databases for relevant clinical studies. The last literature search in databases was performed in June 2020.Eligibility criteria for study selectionWe included studies exploring the associations between CE and the outcomes of EVT in patients with AIS undergoing EVT.Data extraction and synthesisTwo reviewers extracted relevant information and data from each article independently. We pooled ORs with CIs using a random-effects meta-analysis to calculate the associations between CE and outcomes of EVT. The magnitude of heterogeneity between estimates was quantified with the I2 statistic with 95% CIs.ResultsFifteen observational studies that enrolled 1897 patients were included. Patients with CE had higher risks of poor functional outcome at discharge (2.38, 95% CI 1.45 to 3.89 p=0.001; n=545) and poor functional outcome at 90 days (OR 2.16, 95% CI 1.20 to 3.90; n=1194). We found no association between CE and in-hospital mortality (OR 0.95, 95% CI 0.27 to 3.30; n=376) or 90-day mortality (OR 1.38, 95% CI 0.81 to 2.36; n=697) after EVT. Moreover, CE was associated with higher risks of post-EVT intracranial haemorrhage (ICH) (OR 6.68, 95% CI 3.51 to 12.70; n=1721) and symptomatic ICH (OR 3.26, 95% CI 1.97 to 5.40; n=1092).ConclusionsThis systematic review and meta-analysis indicates that in patients with AIS undergoing EVT, CE is associated with higher risks of unfavourable functional outcomes and ICH. Thus, we should pay more attention to CE in patients with AIS undergoing EVT.

Download Full-text

Association between insulin resistance and post-ischaemic stroke outcome in patients without diabetes: protocol for a systematic review and meta-analysis

BMJ Open ◽

10.1136/bmjopen-2020-044771 ◽

2021 ◽

Vol 11 (3) ◽

pp. e044771

Author(s):

Jeremiah Hadwen ◽

Woojin Kim ◽

Brian Dewar ◽

Tim Ramsay ◽

Alexandra Davis ◽

...

Keyword(s):

Systematic Review ◽

Insulin Resistance ◽

Ischaemic Stroke ◽

Functional Outcome ◽

Recurrent Stroke ◽

Meta Analysis ◽

Secondary Outcome ◽

Stroke Outcome ◽

Post Stroke ◽

Meta Analyses

IntroductionInsulin resistance is an independent risk factor for atherosclerosis, coronary artery disease and ischaemic stroke. Currently, insulin resistance is not usually included in post-stroke risk stratification. This systematic review and meta-analysis intends to determine if available scientific knowledge supports an association between insulin resistance and post-stroke outcomes in patients without diabetes.Methods and analysisThe authors will conduct a literature search in Medline, Embase, Web of Science and Cochrane Central. The review will include studies that assess the association between elevated insulin homeostasis model of insulin resistance (HOMA-IR) and post-stroke outcome (functional outcome and recurrent stroke). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines will be used. The primary outcome will be post-stroke functional outcome (Modified Rankin Scale), and the secondary outcome will be recurrent ischaemic stroke. Comparison of outcome will be made between highest and lowest HOMA-IR range (as defined in each article included in this systematic review). Risk of bias will be assessed qualitatively. Meta-analysis will be performed if sufficient homogeneity exists between studies. Heterogeneity of outcomes will be assessed by I².Ethics and disseminationNo human or animal subjects or samples were/will be used. The results will be published in a peer-reviewed journal, and will be disseminated at local and international neurology conferences.PROSPERO registration numberCRD42020173608.

Download Full-text

Differences in Acute Ischemic Stroke Management and Prognosis between Multiple Large-Vessel Occlusion and Single Large-Vessel Occlusion: Subanalysis of the RESCUE-Japan Registry 2

Cerebrovascular Diseases ◽

10.1159/000514369 ◽

2021 ◽

Vol 50 (4) ◽

pp. 397-404

Author(s):

Kotaro Tatebayashi ◽

Kazutaka Uchida ◽

Hiroto Kageyama ◽

Hirotoshi Imamura ◽

Nobuyuki Ohara ◽

...

Keyword(s):

Ischemic Stroke ◽

Acute Ischemic Stroke ◽

Patient Characteristics ◽

Large Vessel ◽

Large Vessel Occlusion ◽

Vessel Occlusion ◽

Endovascular Thrombectomy ◽

Tandem Occlusion ◽

The Mean ◽

Patient Prognosis

Introduction: The management and prognosis of acute ischemic stroke due to multiple large-vessel occlusion (LVO) (MLVO) are not well scrutinized. We therefore aimed to elucidate the differences in patient characteristics and prognosis of MLVO and single LVO (SLVO). Methods: The Recovery by Endovascular Salvage for Cerebral Ultra-Acute Embolism Japan Registry 2 (RESCUE-Japan Registry 2) enrolled 2,420 consecutive patients with acute LVO who were admitted within 24 h of onset. We compared patient prognosis between MLVO and SLVO in the favorable outcome, defined as a modified Rankin Scale (mRS) score ≤2, and in mortality at 90 days by adjusting for confounders. Additionally, we stratified MLVO patients into tandem occlusion and different territories, according to the occlusion site information and also examined their characteristics. Results: Among the 2,399 patients registered, 124 (5.2%) had MLVO. Although there was no difference between the 2 groups in terms of hypertension as a risk factor, the mean arterial pressure on admission was significantly higher in MLVO (115 vs. 107 mm Hg, p = 0.004). MLVO in different territories was more likely to be cardioembolic (42.1 vs. 10.4%, p = 0.0002), while MLVO in tandem occlusion was more likely to be atherothrombotic (39.5 vs. 81.3%, p < 0.0001). Among MLVO, tandem occlusion had a significantly longer onset-to-door time than different territories (200 vs. 95 min, p = 0.02); accordingly, the tissue plasminogen activator administration was significantly less in tandem occlusion (22.4 vs. 47.9%, p = 0.003). However, interestingly, the endovascular thrombectomy (EVT) was performed significantly more in tandem occlusion (63.2 vs. 41.7%; adjusted odds ratio [aOR], 2.3; 95% confidence interval [CI], 1.1–5.0). The type of MLVO was the only and significant factor associated with EVT performance in multivariate analysis. The favorable outcomes were obtained less in MLVO than in SLVO (28.2 vs. 37.1%; aOR, 0.48; 95% CI, 0.30–0.76). The mortality rate was not significantly different between MLVO and SLVO (8.9 vs. 11.1%, p = 0.42). Discussion/Conclusion: The prognosis of MLVO was significantly worse than that of SLVO. In different territories, we might be able to consider more aggressive EVT interventions.

Download Full-text

Clinical Considerations for Return to Driving a Car following a Total Knee or Hip Arthroplasty: A Systematic Review

BioMed Research International ◽

10.1155/2020/8921892 ◽

2020 ◽

Vol 2020 ◽

pp. 1-10

Author(s):

Annalisa Na ◽

Kacy Richburg ◽

Zbigniew Gugala

Keyword(s):

Systematic Reviews ◽

Hip Arthroplasty ◽

Response Times ◽

Meta Analysis ◽

Patient Characteristics ◽

Postoperative Management ◽

Cochrane Library ◽

Clinical Factors ◽

Study Results ◽

Meta Analyses

Aim. The purpose of this study is to systematically review patient characteristics and clinical determinants that may influence return to driving status and time frames following a primary TKA or THA and provide an update of the current literature. Methods. This review was completed per the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Final electronic database searches were completed in October 2019 in Medline/PubMed, Medline/OVID, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Cochrane Library using preselected search terms. Manuscripts of prospective and nonrandomized studies that examined the return to driving a car after a primary knee or hip arthroplasty patients were included. The Methodological Index for Non-Randomized Studies was used to measure study quality. Two authors selected studies and assessed their qualities. All disagreements were resolved through discussion and, as needed, a third reviewer. Data on study title, author(s), country, year, study design, sample size, inclusion and exclusion criteria, age, BMI, gender, statistical analyses, driving measure, follow-up time, surgical approach, laterality, and postoperative management were extracted from each study. Results. A total of 23 studies were eligible, including 12 TKA studies (n=654) with mean ages between 43 and 82 years, 9 THA studies (n=922) with mean ages between 34 and 85 years, and 2 combined TKA and THA (TKA, n=815; THA, n=685), yielded MINORS scores between 6 and 12. Most patients achieved or exceeded preoperative response times between 1 and 8 weeks following a TKA and 2 days to 8 weeks following a THA, and/or self-reported return to driving between 1 week and 6 months. Influences on return to driving time included laterality and pain, but gender was mixed. Discussion/Conclusions. Study results were consistent with previous systematic reviews in that return to driving a car after a primary TKA or THA is highly variable, and most commonly occurs around 4 weeks, but can range between 2 and 8 weeks. While various patient and clinical factors can influence return to driving for a TKA or THA, the most common contributing facts were pain and laterality. The heterogeneous nature of the studies prevented a meta-analysis for determining contributions of return to driving following a primary TKA or THA. Regardless, this study updates previous systematic reviews and presents insight on patient and clinical factors beyond generalized timeframes for return to driving a car. This information and results from future studies are essential to guide clinical recommendations and patient and clinician expectations for return to driving a car after a primary TKA or THA.

Download Full-text

Clinical Outcomes of Tanezumab With Different Dosages for Patient With Osteoarthritis: Network Meta-Analysis

Frontiers in Pharmacology ◽

10.3389/fphar.2021.614753 ◽

2021 ◽

Vol 12 ◽

Author(s):

Rui Hu ◽

Ya-Feng Song ◽

Zhi-Yan Yang ◽

Chao Zhang ◽

Bo Tan

Keyword(s):

Statistical Difference ◽

Meta Analysis ◽

Interaction Model ◽

The Other ◽

Clinical Effects ◽

Disability Rate ◽

Safety Event ◽

Treatment Interaction ◽

The Difference ◽

Meta Analyses

Background: Osteoarthritis (OA) high disability rate will increase as people getting older, and is the most prevalent form of arthritis in the future. This study identified the clinical effects of optimum doses of tanezumab for patients with OA.Method: Three electronic databases were searched up until January 15, 2021. The mean difference (MD) or odds ratio (OR) was considered an effect measure. The design-by-treatment interaction model was adopted for network meta-analyses. Analyses were conducted using WinBUGS 1.4.3 and R 4.0.5 software.Results: nine publications with 10 studies were included. Compared with placebo in network meta-analysis, except the outcomes of Western Ontario and McMaster Universities Osteoarthritis (WOMAC) stiffness subscale and joints replaced, all dosages of tanezumab in the other effectiveness outcome were superior to placebo, and the difference was statistically significant. However, there was no statistical difference among all different doses of tanezumab. Compared with placebo, except the outcomes of adverse events (AEs) and AEs of abnormal peripheral sensation, all different dosages of tanezumab weren’t superior to placebo in the other effectiveness outcome, and the difference was statistically significant. The 10 mg of tanezumab with highest SUCRA had the best effect, but it was associated with a higher safety event. Compared with placebo, except the outcomes of WOMAC stiffness subscale and joints replaced, all dosages of tanezumab in the other effectiveness outcome were superior to placebo, and the difference was statistically significant. Compared with placebo, except for the outcomes of AEs and AEs of abnormal peripheral sensation, all dosages of tanezumab in the other effectiveness outcome were superior to placebo, and the difference was statistically significant. Other direct comparisons showed no statistical difference.Conclusion: This study recommended that clinicians should give priority to the treatment of OA patients with a low dose of 2.5 mg according to the patient’s condition and actual situation. If the effect using tanezumab with 2.5 mg is not satisfactory, the increase up to 10 mg should be carefully pondered, because of a more unbalanced risk/benefit ratio.

Download Full-text

Prevalence of the Use of Herbal Medicines among Patients with Cancer: A Systematic Review and Meta-Analysis

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2021/9963038 ◽

2021 ◽

Vol 2021 ◽

pp. 1-18

Author(s):

John Baptist Asiimwe ◽

Prakash B. Nagendrappa ◽

Esther C. Atukunda ◽

Mauda M. Kamatenesi ◽

Grace Nambozi ◽

...

Keyword(s):

Herbal Medicine ◽

Meta Analysis ◽

Herbal Medicines ◽

Patient Characteristics ◽

Medicine Use ◽

Middle Income ◽

Patients With Cancer ◽

Pooled Prevalence ◽

Prevalence Estimates ◽

Meta Analyses

Background. Although herbal medicines are used by patients with cancer in multiple oncology care settings, the magnitude of herbal medicine use in this context remains unclear. The purpose of this review was to establish the prevalence of herbal medicine use among patients with cancer, across various geographical settings and patient characteristics (age and gender categories). Methods. Electronic databases that were searched for data published, from January 2000 to January 2020, were Medline (PubMed), Google Scholar, Embase, and African Index Medicus. Eligible studies reporting prevalence estimates of herbal medicine use amongst cancer patients were pooled using random-effects meta-analyses. Studies were grouped by World Bank region and income groups. Subgroup and meta-regression analyses were performed to explore source of heterogeneity. Results. In total, 155 studies with data for 809,065 participants (53.95% female) met the inclusion criteria. Overall, the pooled prevalence of the use of herbal medicine among patients with cancer was 22% (95% confidence interval (CI): 18%–25%), with the highest prevalence estimates for Africa (40%, 95% CI: 23%–58%) and Asia (28%, 95% CI: 21%–35%). The pooled prevalence estimate was higher across low- and middle-income countries (32%, 95% CI: 23%–42%) and lower across high-income countries (17%, 95% CI: 14%–21%). Higher pooled prevalence estimates were found for adult patients with cancer (22%, 95% CI: 19%–26%) compared with children with cancer (18%, 95% CI: 11%–27%) and for female patients (27%, 95% CI: 19%–35%) compared with males (17%, 95% CI: 1%–47%). Conclusion. Herbal medicine is used by a large percentage of patients with cancer use. The findings of this review highlight the need for herbal medicine to be integrated in cancer care.

Download Full-text

Glycated Hemoglobin as a Marker for Predicting Outcomes of Patients With Stroke (Ischemic and Hemorrhagic): A Systematic Review and Meta-Analysis

Frontiers in Neurology ◽

10.3389/fneur.2021.642899 ◽

2021 ◽

Vol 12 ◽

Author(s):

Yaya Bao ◽

Dadong Gu

Keyword(s):

Functional Outcome ◽

Hemorrhagic Stroke ◽

Glycated Hemoglobin ◽

Meta Analysis ◽

Poor Functional Outcome ◽

Risk Of Mortality ◽

Increased Risk ◽

Unit Increase ◽

Symptomatic Intracranial Hemorrhage ◽

The Relationship

Background: Glycated hemoglobin (HbA1c) has emerged as a useful biochemical marker reflecting the average glycemic control over the last 3 months, and the values are not affected by short-term transient changes in blood glucose levels. However, its prognostic value in the acute neurological conditions such as stroke is still not well-established. The present meta-analysis was conducted to assess the relationship of HbA1c with outcomes such as mortality, early neurological complications, and functional dependence in stroke patients.Methods: A systematic search was conducted for the PubMed, Scopus, and Google Scholar databases. Studies, either retrospective or prospective in design that examined the relationship between HbA1c with outcomes of interest and presented the strength of association in the form of adjusted odds ratio/hazard ratios were included in the review. Statistical analysis was done using STATA version 13.0.Results: A total of 22 studies (15 studies on acute ischemic stroke and seven studies on hemorrhagic stroke) were included in the meta-analysis. For patients with acute ischemic stroke, each unit increase in HbA1c was found to be associated with an increased risk of mortality within 1 year, increased risk of poor functional outcome at 3 months, and an increased risk of symptomatic intracranial hemorrhage (sICH) within 24 h of admission. In those with HbA1c ≥ 6.5%, there was an increased risk of mortality within 1 year of admission, increased risk of poor functional outcomes at 3 and 12 months as well as an increased risk of symptomatic intracranial hemorrhage (sICH) within 24 h of admission. In patients with hemorrhagic stroke, each unit increase in HbA1c was found to be associated with increased risk of poor functional outcome within the first 3 months from the time of admission for stroke. In those with HbA1c ≥ 6.5%, there was an increased risk of poor functional outcome at 12 months.Conclusions: The findings indicate that glycated hemoglobin (HbA1c) could serve as a useful marker to predict the outcomes in patients with stroke and aid in the implementation of adequate preventive management strategies at the earliest.

Download Full-text

A comparison of biologics in first-line advanced colorectal cancer: A Bayesian network meta-analysis of EGFR inhibitors and bevacizumab.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.3_suppl.543 ◽

2014 ◽

Vol 32 (3_suppl) ◽

pp. 543-543 ◽

Cited By ~ 1

Author(s):

Alexander Kumachev ◽

Marie Yan ◽

Scott R. Berry ◽

Yoo-Joung Ko ◽

Maria Carmen Riesco Martinez ◽

...

Keyword(s):

Direct Evidence ◽

Advanced Colorectal Cancer ◽

Meta Analysis ◽

Patient Characteristics ◽

Egfr Inhibitors ◽

First Line ◽

Hazard Ratios ◽

Improved Outcomes ◽

Meta Analyses ◽

Indirect Comparisons

543 Background: Adding bevacizumab (B) or EGFR inhibitors (E) to chemotherapy have improved outcomes when compared to chemotherapy (chemo) alone in the first-line treatment of mCRC, however it is unclear which of these combinations is optimal. As the 2 RCTs presented to date were not powered to detect overall survival (OS) benefits and have shown conflicting OS results, a meta-analysis may be beneficial. Methods: We conducted a systematic review of RCTs comparing (1) E + chemo vs. B + chemo (2) E + chemo vs. chemo only, or (3) B + chemo vs. chemo only, using MEDLINE, Embase, Cochrane Central, and ASCO abstracts up to June 2013 with Cochrane methodology. Data on PFS and OS were extracted using the Parmar method. For RCTs involving E, only the K-ras WT data was included. The patient characteristics and outcomes of the reference arms of the RCTs were examined to assess for heterogeneity. Bayesian pairwise and network meta-analyses (NMA) were conducted to estimate the direct, indirect and combined PFS and OS hazard ratios comparing E to B using WinBUGs. Results: Seventeen RCTs (8,048 patients) were identified; 15 of them contained extractable data for quantitative analysis. Direct pairwise meta-analyses (2 RCTs) comparing E vs. B showed that PFS HR=1.00 (95% credible regions (CR): 0.86-1.17) and OS HR=0.76 (95% CR: 0.63-0.92) in favour of E. Indirect comparisons of E vs. B (through the intermediate of chemo only: 5 RCTs comparing E + chemo vs. chemo only, 8 RCTs comparing B + chemo vs. chemo only) showed that PFS HR=1.31 (95% CR: 0.98-1.85) and OS HR=1.06 (95% CR: 0.93-1.22). Combining direct and indirect comparisons with NMA (15 RCTs) showed that the PFS HR=1.10 (95% CR: 1.00-1.21) (trend in favour of B) and OS HR=0.95 (95% CR: 0.85-1.06). Conclusions: The results of direct pairwise meta-analysis, dominated mostly by FIRE-3, suggested E improves OS without PFS benefits when compared to B. However, the results from indirect or combined NMA synthesizing all relevant data from the existing literature did not confirm those findings. The findings of FIRE-3 may be due to chance or trial specific reasons. The results of the upcoming CALGB 80405 will provide further direct evidence to help refine these estimates.

Download Full-text

Abstract 1122‐000083: Endovascular Therapy Delay for Acute LVO is Associated with Worse Functional Outcome and Increased Mortality

Stroke: Vascular and Interventional Neurology ◽

10.1161/svin.01.suppl_1.000083 ◽

2021 ◽

Vol 1 (S1) ◽

Author(s):

Julian Carrion‐Penagos ◽

Sonam Thind ◽

Elisheva Coleman ◽

James R Brorson ◽

...

Keyword(s):

Functional Outcome ◽

Functional Outcomes ◽

Lower Probability ◽

Modified Rankin Scale ◽

Poor Functional Outcome ◽

Vessel Occlusion ◽

Living Situation ◽

Comprehensive Stroke Center ◽

Stroke Center ◽

Relevant Covariates

Introduction : The importance of early mechanical thrombectomy (MT) has shown to improve functional outcomes for patients with acute large vessel occlusion (LVO). As well, prior studies have shown that earlier MT resulted in reduced hospital stay, more home‐time, and more desirable living situation in the 90 days after stroke. We hypothesized that delay in MT in patients with LVO would result in worse clinical outcome and increased mortality. Methods : We performed a retrospective analysis of consecutive patients who underwent MT for LVO in a large academic comprehensive stroke center between 01/2018 and 05/2021. We compared outcomes including in‐hospital mortality and 90‐day modified Rankin Scale (mRS) based on time from door‐to‐puncture and door‐to‐reperfusion, adjusting for relevant covariates using logistic regression. Results : Patients that had shorter door‐to‐puncture time were found to have higher probability of a lower modified Rankin Scale (mRS 0–2) at discharge (p = 0.03). Patients with door‐to‐puncture less than 60 minutes had a probability of 50% of achieving a good outcome. Longer door‐to‐puncture times were associated with lower probability of achieving mRS 0–2 at discharge. A similar finding was seen in patients that had shorter times to reperfusion (p = 0.05). Adjusting for age, baseline NIHSS score, and final TICI score, delayed door‐to‐reperfusion time in minutes was an independent predictor of increased mortality at 90 days of 9% for every 10 minutes delay (OR 1.009, 95% CI 1.003‐1.016, p = 0.006). Every 10 minutes delay in door‐to‐reperfusion time had 7% higher chance of poor functional outcome at 90 days (OR 1.007, 95% CI 1.004‐1.019, p = 0.015). Conclusions : Shorter times to MT and reperfusion impact functional outcome and mortality in LVO stroke patients. This indicates that an adequate hospital protocol and continuous education may lead to faster and more efficient stroke activations leading to a shorter time to MT and eventual reperfusion. Goals of door‐to‐puncture must be established in order to achieve better outcomes.

Download Full-text